Highly likely that one of the first duties that Dr. Krause will be performing as a Director for MSB will be to review with a fine tooth comb the submission for AGVHD and give feedback on what needs to be tidied up to give the maximum chance of approval by FDA .... This in itself could take a while -.prior to getting the submission out the door....
This appointment is invaluable to MSB given our recent history with FDA...
It shows again how incredibly seriously SI is taking the task of getting our first approval ...we are at a pivotal time crucial to the companies success / so no stones left unturned ....and the time is now !
Ann: Director Appointment, page-96
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $4.391M | 3.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 48253 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 32922 | 2 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |